{"id":"NCT01663532","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia","officialTitle":"A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2013-08","completion":"2013-09","firstPosted":"2012-08-13","resultsPosted":"2015-02-16","lastUpdate":"2015-02-16"},"enrollment":340,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Aripiprazole IM Depot","otherNames":["OPC-14597","Lu AF41155"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Aripiprazole IM Depot","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to evaluate the overall efficacy of aripiprazole intramuscular (IM) depot as acute treatment in subjects with schizophrenia.\n\nThe secondary purpose is to evaluate the safety and tolerability of aripiprazole IM depot administered every 4 weeks for 12 weeks to adult subjects with schizophrenia.","primaryOutcome":{"measure":"Mean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score.","timeFrame":"Baseline to Week 10","effectByArm":[{"arm":"Aripiprazole IM Depot 400/300mg","deltaMin":-8.9,"sd":0.9},{"arm":"Placebo","deltaMin":-5,"sd":0.9}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0005"},{"comp":"OG000 vs OG001","p":"<.0001"},{"comp":"OG000 vs OG001","p":"<.0001"},{"comp":"OG000 vs OG001","p":"<.0001"},{"comp":"OG000 vs OG001","p":"<.0001"},{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":10},"locations":{"siteCount":49,"countries":["United States","Croatia","Latvia"]},"refs":{"pmids":["25188501"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":167},"commonTop":["Headache","Weight increased","Constipation","Akathisia","Dyspepsia"]}}